David Setboun

David Setboun, Pharm.D., MBA is a seasoned pharmaceutical executive with extensive experience in corporate development, strategy, and commercial operations. He is currently serving as the Chief Operating Officer at Alkeus Pharmaceuticals, Inc., a position he has held since May 2023.1 Alkeus is a late-stage biopharmaceutical company focused on developing treatments for serious, progressive eye diseases that lead to blindness.1

Prior to his current role, Setboun served as the Executive Vice President & Chief Operating Officer at Brainstorm Cell Therapeutics from April 2020 to May 2023.1 During his tenure at Brainstorm, the company made significant progress in developing treatments for amyotrophic lateral sclerosis (ALS).4

Setboun's career history includes several leadership positions in the pharmaceutical industry:

• Vice President of Corporate Development & Strategy at Life Biosciences (2018-2020)
• Vice President and Managing Director France at Biogen (2015-2018)
• Country President for Portugal at AstraZeneca (2012-2015)
• Sales & Marketing Director Europe at AstraZeneca (2009-2012)
• Global / International Brand Director at Eli Lilly in Indianapolis, USA (2007-2009)1

In terms of education, Setboun holds a Doctor of Pharmacy (Pharm.D.) from Université Paris Sud (Paris XI) and an MBA from HEC School of Management. He has also completed executive education programs at the Massachusetts Institute of Technology and Harvard Business School.1

Setboun is multilingual, with proficiency in several languages including French, English, Portuguese, Spanish, and Italian.1 He is also involved with the Academy for Health & Lifespan Research, where he serves as President, working to accelerate breakthroughs in longevity research.1

In his current role at Alkeus Pharmaceuticals, Setboun is involved in the development of ALK-001, an oral investigational drug for the treatment of Stargardt disease and Geographic Atrophy secondary to dry age-related macular degeneration.12 The company has recently presented positive data from their TEASE-1 clinical trial for Stargardt disease at the American Academy of Ophthalmology (AAO) 2023 conference.23